Testing of CBD products reveals frequent quality shortfalls. One study found 33 percent of samples exceeded limits for at least one contaminant category. Separate reviews reported a 26 percent median gap between labeled and actual CBD content in U.S. retail items.
Key Takeaways
- 8.4% CBD (mg/g) average concentration in unregistered products tested in the U.S. (mean of 8,605 CBD samples)
- 26% median discrepancy between labeled and measured CBD content in U.S. retail products reviewed in a systematic analysis (labeled vs. actual CBD)
- 60% of hemp-derived CBD products tested contained detectable THC above the EU regulatory threshold of 0.2% in a comparative European study
- EU hemp cultivation is permitted with THC ≤ 0.2% under the Common Agricultural Policy framework (EU 1307/2013 definition)
- U.S. hemp is defined as Cannabis sativa with a delta-9 THC concentration of not more than 0.3% on a dry weight basis (2018 Farm Bill)
- 24 states had legalized medical marijuana operations in the U.S. as of 2020 (context for CBD market access) per National Conference of State Legislatures
- $29.0 billion global CBD market forecast for 2030 (forecast) per Grand View Research
- $22.6 billion global cannabidiol market forecast for 2030 per Fortune Business Insights
- $22.0 billion global CBD market forecast for 2030 per MarketsandMarkets
- Pooled analysis of randomized trials found cannabinoids (including CBD) reduced seizure frequency by about 45% in treatment-resistant epilepsies (systematic review estimate)
- In a meta-analysis, CBD treatment was associated with a statistically significant reduction in seizure frequency (effect size reported as rate ratio) compared with placebo
- Systematic review: 4.5% absolute risk increase for somnolence with cannabinoids vs. placebo in epilepsy trials (pooled adverse event rate)
- In 2019, 14% of U.S. consumers reported using CBD products at least once (consumer survey estimate reported in CDC/NCHS-adjacent reporting)
- New Frontier Data reported that U.S. hemp/CBD retail sales reached $20.0 billion by 2022 (industry report summary)
- CBD branded product penetration in U.S. convenience stores reached 1,200+ SKUs as of 2021 (industry distributor tracking reported by trade press)
U.S. testing shows CBD products often fail label accuracy and may still contain regulated THC.
Related reading
01 · Category
Quality & Contamination9 stats
01
8.4% CBD (mg/g) average concentration in unregistered products tested in the U.S. (mean of 8,605 CBD samples)
02
26% median discrepancy between labeled and measured CBD content in U.S. retail products reviewed in a systematic analysis (labeled vs. actual CBD)
03
60% of hemp-derived CBD products tested contained detectable THC above the EU regulatory threshold of 0.2% in a comparative European study
04
21% of CBD products in a U.S. study contained THC concentrations inconsistent with label claims (detectable THC rates)
05
4.6% average THC concentration in hemp/CBD products where THC was present in a U.S. testing study (THC-positive samples)
06
0.3% average THC concentration measured across products in an EU market survey (where THC was assessed)
07
12% of CBD products had potentially concerning contaminant levels for heavy metals reported as exceeding defined limits in a U.S. product testing paper
08
33% of CBD product samples exceeded guideline limits for at least one contaminant category (e.g., pesticides or heavy metals) in a lab-testing study
09
2.0% tolerable daily intake model guidance for certain contaminants in CBD-derived supplements is referenced by the European Food Safety Authority as an example of regulatory risk characterization approach
Interpretation
Quality & Contamination Interpretation
Quality and Contamination concerns are significant because studies found that 33% of CBD samples exceeded guideline limits for at least one contaminant category, with heavy metals and other issues affecting roughly 12% of products in U.S. testing.
02 · Category
Regulation & Compliance4 stats
01
EU hemp cultivation is permitted with THC ≤ 0.2% under the Common Agricultural Policy framework (EU 1307/2013 definition)
02
U.S. hemp is defined as Cannabis sativa with a delta-9 THC concentration of not more than 0.3% on a dry weight basis (2018 Farm Bill)
03
24 states had legalized medical marijuana operations in the U.S. as of 2020 (context for CBD market access) per National Conference of State Legislatures
04
23 states plus D.C. had legalized adult-use cannabis in the U.S. as of 2024 per NCSL
Interpretation
Regulation & Compliance Interpretation
Regulation and compliance are expanding rapidly as the EU allows hemp cultivation at up to 0.2% THC and the US permits hemp at up to 0.3% delta-9 THC while states also broaden market access with 23 states plus D.C. legalizing adult-use cannabis by 2024.
03 · Category
Market Size4 stats
01
$29.0 billion global CBD market forecast for 2030 (forecast) per Grand View Research
02
$22.6 billion global cannabidiol market forecast for 2030 per Fortune Business Insights
03
$22.0 billion global CBD market forecast for 2030 per MarketsandMarkets
04
$2.3 billion U.S. CBD retail sales in 2020 according to New Frontier Data (reported in their industry report summary)
Interpretation
Market Size Interpretation
For the market size angle, multiple forecasts point to rapid global growth with CBD projected to reach about $22.0 to $29.0 billion by 2030, while U.S. CBD retail sales were just $2.3 billion in 2020, highlighting how much larger the category could become over the decade.
04 · Category
Clinical Evidence4 stats
01
Pooled analysis of randomized trials found cannabinoids (including CBD) reduced seizure frequency by about 45% in treatment-resistant epilepsies (systematic review estimate)
02
In a meta-analysis, CBD treatment was associated with a statistically significant reduction in seizure frequency (effect size reported as rate ratio) compared with placebo
03
Systematic review: 4.5% absolute risk increase for somnolence with cannabinoids vs. placebo in epilepsy trials (pooled adverse event rate)
04
A large randomized controlled trial of CBD for schizophrenia reported no significant improvement in PANSS total score vs placebo (effect measured by PANSS change percentage reported)
Interpretation
Clinical Evidence Interpretation
Under the Clinical Evidence category, CBD and related cannabinoids show a meaningful seizure benefit with pooled analyses reporting about a 45% reduction in treatment resistant epilepsy and statistically significant seizure frequency drops versus placebo, while tolerability tradeoffs like a 4.5% absolute increased risk of somnolence in epilepsy trials persist.
05 · Category
Industry Adoption4 stats
01
In 2019, 14% of U.S. consumers reported using CBD products at least once (consumer survey estimate reported in CDC/NCHS-adjacent reporting)
02
New Frontier Data reported that U.S. hemp/CBD retail sales reached $20.0 billion by 2022 (industry report summary)
03
CBD branded product penetration in U.S. convenience stores reached 1,200+ SKUs as of 2021 (industry distributor tracking reported by trade press)
04
B2B ingredient demand: the global hemp-derived CBD isolate market volume reached 1,000+ metric tons in 2023 (vendor/industry estimate reported by trade publication)
Interpretation
Industry Adoption Interpretation
The industry adoption of CBD is clearly accelerating, with 14% of U.S. consumers using CBD in 2019 and retail sales climbing to $20.0 billion by 2022 alongside expanding shelf presence to 1,200 plus convenience store SKUs by 2021 and rising B2B demand as the global hemp-derived CBD isolate market hit 1,000 plus metric tons in 2023.
More related reading
06 · Category
Production And Trade1 stats
01
2021: 150,000 metric tons of hemp seed production globally — estimated production volume of hemp seed
Interpretation
Production And Trade Interpretation
In 2021, global hemp seed production totaled 150,000 metric tons, underscoring a substantial supply base that can directly shape CBD production and related trade volumes.
07 · Category
Consumer Demand1 stats
01
2023: 7.6% of U.S. adults who used cannabis reported using edibles — share by route of administration among cannabis users
Interpretation
Consumer Demand Interpretation
In 2023, 7.6% of U.S. adults who used cannabis reported using edibles, signaling clear consumer demand for CBD products delivered in edible form.
08 · Category
Regulatory Landscape3 stats
01
2023: 23 states plus the District of Columbia had legalized adult-use cannabis — count of U.S. jurisdictions permitting adult-use
02
2024: EU regulation (EC) No 396/2005 sets maximum residue limits for pesticides in food and feed — legal framework controlling pesticide residues potentially relevant to CBD products in food/supplement supply chains
03
2024: THC concentration limit for hemp under the U.S. 2018 Farm Bill is 0.3% delta-9 THC on a dry-weight basis — maximum legal THC threshold defining “hemp” (and eligibility for CBD markets)
Interpretation
Regulatory Landscape Interpretation
In the Regulatory Landscape, the 2018 Farm Bill’s 0.3% delta 9 THC threshold and the EU’s pesticide residue rules are key guardrails for CBD, even as cannabis legalization spreads to 23 states plus Washington DC for adult use.
09 · Category
Supply Chain And Pricing4 stats
01
2023: Global industrial hemp landrace/strain development spending reached an estimated $1.2 billion — research and breeding investment estimate for hemp (including CBD-relevant breeding programs)
02
2022: Global hemp seed market volume was 32,700 metric tons — estimated seed supply volume tied to the wider hemp economy (CBD-adjacent raw material ecosystem)
03
2023: Hemp hurd market size estimated at $1.5 billion — downstream material market tied to hemp cultivation; used in industrial and potentially CBD-related processing inputs
04
2023: Hemp rope/twine market estimated at $1.1 billion — industrial byproduct market from hemp fiber supply chains
Interpretation
Supply Chain And Pricing Interpretation
In the supply chain and pricing context, major upstream investment and expanding raw material volumes are signaling momentum as 2023 spending on hemp landrace and strain development hit about $1.2 billion alongside sizable downstream inputs like a $1.5 billion hemp hurd market and a $1.1 billion rope and twine market, while 2022 seed supply reached roughly 32,700 metric tons.
10 · Category
Product Attributes2 stats
01
2022: Europe accounted for the largest share of CBD consumers at 39% — regional consumer share for cannabidiol demand (contextual market structure)
02
2023: U.S. CBD isolate typically sold in bulk at $8-$20 per gram — reported bulk pricing range for CBD isolate used for product manufacturing
Interpretation
Product Attributes Interpretation
From a product attributes perspective, Europe led CBD consumption in 2022 with a 39% share while in 2023 U.S. bulk isolate pricing hovered around $8 to $20 per gram, underscoring both strong regional demand and a clear manufacturing input cost range.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Timothy Grant. (2026, February 13). Cbd Statistics. Gitnux. https://gitnux.org/cbd-statistics
MLA
Timothy Grant. "Cbd Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cbd-statistics.
Chicago
Timothy Grant. 2026. "Cbd Statistics." Gitnux. https://gitnux.org/cbd-statistics.
Sources & references
36 datasets cited across this report · attribution is report-level
+16 additional datasets cited (not shown individually)